Original Articles: Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
نویسندگان
چکیده
Summary Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses of primary and secondary end points included LMM using all subject data and mixed model repeated measures (MMRM) of change from baseline at each year. Pearson correlation tested the association between log-TKV and eGFR changes. Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls 1422, tolvaptan 1635 ml) and eGFR (both 62 ml/min per 1.73 m ) were similar. Control TKV increased 5.8% versus 1.7%/yr for tolvaptan (P < 0.001, estimated ratio of geometric mean 0.96 [95% confidence interval 0.95 to 0.97]). Corresponding annualized eGFR declined: −2.1 versus −0.71 ml/min per 1.73 m /yr (P = 0.01, LMM group difference 1.1 ml/min per 1.73 m /yr [95% confidence interval 0.24 to 1.9]). Sensitivity analyses including withdrawn subjects were similar, whereas MMRM analyses were significant at each year for TKV and nonsignificant for eGFR. Increasing TKV correlated with decreasing eGFR (r = −0.21, P < 0.01). Conclusion ADPKD cyst growth progresses more slowly with tolvaptan than in historical controls, but AEs are common. Introduction Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder which, over decades, results in progressive development of multiple renal cysts, urinary concentration defects, hypertension, and ultimately ESRD (1–4). Kidney and back pain from cyst hemorrhage, stones, infection, biomechanical stresses, stretching of the renal capsule, or pressure on other organs can impact quality of life (5). Less common extrarenal manifestations such as cerebral aneurysms may be lifethreatening. Studies in animal models have implicated arginine vasopressin and its second messenger cAMP as important promoters of cyst cell proliferation and fluid secretion into cysts (6). Suppression of vasopressin release by forced hydration, genetic crosses between cyst-prone animals and those lacking vasopressin, and vasopressin V receptor blockade consistently reduce cyst burden and protect renal function (6). These compelling preclinical studies provided a rationale for vasopressin V receptor antagonism as a preventive therapy for human ADPKD. Total kidney volume (TKV) is a practical, intermediate end point of later outcomes in ADPKD including pain, hypertension, renal insufficiency, and ESRD. The Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) and other studies are establishing the relationship between TKV growth and important clinical outcomes (7–9). However, it will take years of study to prove whether a treatment that slows TKV expansion will positively affect estimated GFR (eGFR), ESRD, or death. The current study explores the potential use of TKV as a surrogate for ADPKD therapies targeting vasopressin V signaling. 4 2
منابع مشابه
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
UNLABELLED Chinese translation BACKGROUND In the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. OBJECTIVE To determine how the benefits of tolvaptan seen in TEMPO may relate to longer-term health outcomes, such as progression to...
متن کاملTolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
BACKGROUND AND OBJECTIVES Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) mea...
متن کاملTolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
Introduction In the randomized placebo-controlled Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD). Consistent with its primary pharmacologic activity, tolvaptan use was commonly associated ...
متن کاملVasopressin antagonists in polycystic kidney disease.
Increased cell proliferation and fluid secretion, probably driven by alterations in intracellular calcium homeostasis and cyclic adenosine 3,5-phosphate, play an important role in the development and progression of polycystic kidney disease. Hormone receptors that affect cyclic adenosine monophosphate and are preferentially expressed in affected tissues are logical treatment targets. There is a...
متن کاملFasting in a 16-year-old girl at-risk of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease that results in renal failure. PKD currently has no causative therapy. However, some treatment options are available, ranging from symptomatic therapy to delaying the onset of end-stage renal failure. Early diagnosis of adult polycystic kidney disease is vital in order to prevent its complic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014